Pemigatinib

證據等級: L5

預測適應症: 10 個

Pemigatinib: From Undocumented Original Indication to Multiple Endocrine Neoplasia

One-Sentence Summary

The evidence pack for pemigatinib does not include original indication data, though the drug is characterized elsewhere in this pack as a selective FGFR1/2/3 kinase inhibitor. The TxGNN model predicts it may be effective for Multiple Endocrine Neoplasia, but this direction currently has 0 clinical trials and 0 publications supporting it, and the model's own rationale flags a lack of mechanistic plausibility.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack (data gap)
Predicted New Indication	Multiple Endocrine Neoplasia
TxGNN Prediction Score	99.71%
Evidence Level	L5
Finland Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for pemigatinib in this evidence pack (flagged as a High-severity data gap). Based on information embedded elsewhere in the pack's repurposing rationales, pemigatinib is consistently described as a selective FGFR1/2/3 kinase inhibitor, consistent with its classification (in an independently retrieved review) among FDA-approved small-molecule protein kinase inhibitors.

For the top-ranked prediction, Multiple Endocrine Neoplasia, the model's own generated rationale is explicitly skeptical: MEN is primarily driven by RET, MEN1, and CDKN1B mutations, none of which have an established link to FGFR signaling. The rationale states this high score likely reflects a lack of underlying mechanistic support rather than a genuine biological signal.

By contrast, a lower-ranked prediction in the same pack — HER2-positive breast carcinoma (rank 3, L4, "Research Question") — has a more coherent mechanistic story (FGFR1 amplification as a known trastuzumab-resistance pathway) and at least one supporting literature reference, even though it still lacks disease-specific data or trials. This suggests the top-ranked prediction may not be the most biologically credible candidate in this pack, and rank 3 may merit separate follow-up.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Finland Market Information

Pemigatinib currently holds no marketing authorizations in Finland (market status: Not Marketed; 0 registered authorizations).

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (FGFR1/2/3 selective kinase inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA package insert warnings/contraindications are marked as a Blocking data gap in this evidence pack — this item must be resolved before any S1 safety assessment can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (Multiple Endocrine Neoplasia) has no clinical trials, no literature, and the model-generated rationale itself questions the mechanistic basis for the score. Combined with the drug's unmarketed status in Finland and a blocking gap in TFDA safety data, there is currently no basis to advance this specific indication.

To proceed, the following is needed:

TFDA/EMA package insert extraction (warnings, contraindications, DDI) — currently a blocking gap
Confirmed original indication and mechanism-of-action data for pemigatinib
Any preclinical or mechanistic evidence directly linking FGFR1/2/3 signaling to MEN pathophysiology
Consider redirecting research attention to the HER2-positive breast carcinoma signal (rank 3, L4), which has a more plausible mechanistic rationale and at least preliminary literature support
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.